What does PHARMA 310505 do?

PHARMA 310505 is a pharmacy in Brugge. Private Limited, started on 2 December 2015, 1 establishment.

What is the address of PHARMA 310505?

The registered office of PHARMA 310505 is located at Koolkerkse Steenweg 150, 8000 Brugge.

Is PHARMA 310505 still active?

Yes. According to the CBE (30 October 2026) PHARMA 310505 is active, legal situation “Normale toestand”, started on 2 December 2015.

Is PHARMA 310505 registered on Peppol?

Yes, PHARMA 310505 is registered on the Peppol network with ID 0208:0643802856.

What is the enterprise number of PHARMA 310505?

The enterprise number of PHARMA 310505 is BE0643802856.

When was PHARMA 310505 founded?

PHARMA 310505 was founded on 2 December 2015.

Who are the directors of PHARMA 310505?

According to the 2025 annual accounts, the directors of PHARMA 310505 are: Strybol Wout Pharma BV, Strybol Iben Pharma BV, Ampuls BV.

Is PHARMA 310505 a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 December 2015; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did PHARMA 310505 make in 2025?

PHARMA 310505 posted a profit after taxes of € 28,950 in financial year 2025.

What is the revenue of PHARMA 310505?

As a small company, PHARMA 310505 is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 110,459.

How many employees does PHARMA 310505 have?

According to the 2025 annual accounts, PHARMA 310505 has 0 full-time equivalents (FTE).

PHARMA 310505 (Private Limited) - Brugge - BE0643802856

Dossier PHARMA 310505, printed on 30 October 2026 from databakkes.be/en/0643802856/pharma-310505. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMA 310505 from Brugge, company number BE0643802856, closed financial year 2025 with a result of € 28,950 after tax. For that financial year PHARMA 310505 recorded a gross margin of € 110,459 and equity of € 413,071. Compared with financial year 2024, the result moved from € 25,865 to € 28,950. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.

What it is worth Growing

€ 413,071

▲ € 328,950 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 28,950

▲ 12% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 409,138

▲ € 402,279 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 94,471.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 506,520

▲ 185% vs 2024

€ 150,254 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 1,588

▲ € 1,261 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,088

▲ 263% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 96,042 Gross margin 2022: € 96,042 First fiscal year in the series	€ 103,868 Gross margin 2023: € 103,868 ▲ 8% vs 2022 (€ 96,042) Favourable step	€ 108,049 Gross margin 2024: € 108,049 ▲ 4% vs 2023 (€ 103,868) Favourable step	€ 110,459 Gross margin 2025: € 110,459 ▲ 2% vs 2024 (€ 108,049) Favourable step	▲ 2%
Profit after taxes	€ 14,162 Profit after taxes 2022: € 14,162 First fiscal year in the series	€ 21,541 Profit after taxes 2023: € 21,541 ▲ 52% vs 2022 (€ 14,162) Favourable step	€ 25,865 Profit after taxes 2024: € 25,865 ▲ 20% vs 2023 (€ 21,541) Favourable step	€ 28,950 Profit after taxes 2025: € 28,950 ▲ 12% vs 2024 (€ 25,865) Favourable step	▲ 12%
Equity	€ 36,715 Equity 2022: € 36,715 First fiscal year in the series	€ 58,256 Equity 2023: € 58,256 ▲ 59% vs 2022 (€ 36,715) Favourable step	€ 84,121 Equity 2024: € 84,121 ▲ 44% vs 2023 (€ 58,256) Favourable step	€ 413,071 Equity 2025: € 413,071 ▲ € 328,950 vs 2024 (€ 84,121) Favourable step	▲ € 328,950
Total debts	€ 327,454 Total debts 2022: € 327,454 First fiscal year in the series	€ 256,663 Total debts 2023: € 256,663 ▼ 22% vs 2022 (€ 327,454) Favourable step	€ 186,670 Total debts 2024: € 186,670 ▼ 27% vs 2023 (€ 256,663) Favourable step	€ 665,425 Total debts 2025: € 665,425 ▲ 256% vs 2024 (€ 186,670) Unfavourable step	▲ 256%
Cash	€ 6,876 Cash 2022: € 6,876 First fiscal year in the series	€ 6,521 Cash 2023: € 6,521 ▼ 5% vs 2022 (€ 6,876) Unfavourable step	€ 6,859 Cash 2024: € 6,859 ▲ 5% vs 2023 (€ 6,521) Favourable step	€ 409,138 Cash 2025: € 409,138 ▲ € 402,279 vs 2024 (€ 6,859) Favourable step	▲ € 402,279
Retained profit	€ 18,115 Retained profit 2022: € 18,115 First fiscal year in the series	€ 39,656 Retained profit 2023: € 39,656 ▲ 119% vs 2022 (€ 18,115) Favourable step	€ 65,521 Retained profit 2024: € 65,521 ▲ 65% vs 2023 (€ 39,656) Favourable step	€ 94,471 Retained profit 2025: € 94,471 ▲ 44% vs 2024 (€ 65,521) Favourable step	▲ 44%
Bank debt	€ 319,500 Bank debt 2022: € 319,500 First fiscal year in the series	€ 248,500 Bank debt 2023: € 248,500 ▼ 22% vs 2022 (€ 319,500) Favourable step	€ 177,500 Bank debt 2024: € 177,500 ▼ 29% vs 2023 (€ 248,500) Favourable step	€ 506,520 Bank debt 2025: € 506,520 ▲ 185% vs 2024 (€ 177,500) Unfavourable step	▲ 185%
Balance sheet total	€ 364,169 Balance sheet total 2022: € 364,169 First fiscal year in the series	€ 314,919 Balance sheet total 2023: € 314,919 ▼ 14% vs 2022 (€ 364,169) Unchanged	€ 270,791 Balance sheet total 2024: € 270,791 ▼ 14% vs 2023 (€ 314,919) Unchanged	€ 1,078,496 Balance sheet total 2025: € 1,078,496 ▲ 298% vs 2024 (€ 270,791) Unchanged	▲ 298%

Key figures of PHARMA 310505, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMA 310505?

What happened at PHARMA 310505 in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 2, 2026 New annual accounts for financial year 2025: profit of € 28,950 (▲ 12% vs 2024). Source: NBB ↗
2026 Strybol Wout Pharma BV became a director. NBB
2026 Strybol Iben Pharma BV became a director. NBB
2026 Ampuls BV became a director. NBB
Jan 1, 2016 New establishment in Brugge. KBO
Dec 2, 2015 Start of the company according to the CBE. KBO

In short

From € 14,162 profit in 2022 to € 28,950 profit in 2025.

Paid € 31,666 in corporate taxes since 2022.

Best year ever: 2025, with € 28,950 profit.

Original PDFs at the National Bank ↗

Management

Strybol Wout Pharma 25%

Strybol Iben Pharma 25%

The stake of Strybol Wout Pharma, Strybol Iben Pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMA 310505

Behind PHARMA 310505 are Strybol Wout Pharma BV, Strybol Iben Pharma BV and Ampuls BV. The shares are held by Strybol Wout Pharma (25%) and Strybol Iben Pharma (25%).

Directors

According to the 2025 annual accounts

Strybol Wout Pharma BV

Director · represented by Strybol Wout

Also active at: STRYBOL DE ZEVEN TORENTJES, APOTHEEK SMEKENS, Strybol Invest, Strybol Pharma Groep, Strybol De Berken, Strybol Sint-Gillis

since 2026

Strybol Iben Pharma BV

Director · represented by Strybol Iben

Also active at: STRYBOL DE ZEVEN TORENTJES, APOTHEEK SMEKENS, Strybol Invest, Strybol Pharma Groep, Strybol De Berken, Strybol Sint-Gillis

since 2026

Ampuls BV

Director · represented by Marie Clyncke

since 2026

Shareholders

Strybol Wout Pharma

25%

Strybol Iben Pharma

25%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Koolkerkse Steenweg 150

8000 Brugge

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0643.802.856

VAT number

BE 0643.802.856

Registered office

Koolkerkse Steenweg 150, 8000 Brugge

Names & denominations

PHARMA 310505

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

2 December 2015

Peppol

Active · Active since 23 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Detailhandel in drogisterijartikelen en onderhoudsproducten

Detailhandel in corrigerende brillen, lenzen en zonnebrillen

Detailhandel in cosmetica en toiletartikelen

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMA 310505

Financials

What happened to PHARMA 310505?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions